CENTENNIAL, Colo., July 1, 2015 /PRNewswire/ -- Cochlear
Limited (ASX: COH), the global leader in implantable hearing
solutions, announced today the US Food and Drug Administration
(FDA) approval of the Cochlear™ Nucleus® Profile™ Implant with Slim
Straight Electrode (CI522). Built on over 30 years of experience
and developed in close collaboration with the world's leading
surgeons, the Profile Series is the thinnest cochlear implant
platform designed to provide the most discreet appearance for both
pediatric and adult cochlear implant users.
"The Nucleus Profile Implant is built on the same reliability
principles that are standard for all of our current and previous
generation devices," said Anthony
Manna, President, Cochlear North America. "This approval
further expands what is already the industry's largest cochlear
implant portfolio and supports a wider range of surgical techniques
among implanting surgeons giving them and their patients the
greatest possible choice."
Combined with the industry's thinnest full length electrode, the
Nucleus Profile with Slim Straight Electrode is the newest in
Cochlear's broad portfolio of electrodes designed for preservation
of delicate cochlear structures, to deliver the best possible full
spectral hearing performance and to accommodate specific
preferences with anatomy and technique in the widest range of
patient conditions. It contours the curvature of the head and is
almost two times stronger than the most reliable implant ever
built, the previous generation Nucleus CI24RE device. Its smooth
surface is designed to minimize the risk of infection, and the
removable magnet is ideally designed for MRI safety and to minimize
image distortion.
"This is fantastic news because it means that more patients can
enjoy the comfort and discreetness of the thin Profile Implant no
matter which electrode is best for them," said Dr. Peter Weber, M.D., MBA, Otolaryngology, UMass
Memorial Medical Center, and Medical Advisor to Cochlear.
People who choose the Nucleus Profile with Slim Straight
Electrode will also receive the market-leading Nucleus 6 Sound
Processor, which delivers more smart features than ever before,
including true 2.4 GHz wireless connectivity and SmartSound® iQ, a
proprietary signal processing platform that automatically adapts to
different acoustic environments. These features are not only
intended to help make listening easier, they are designed to help
users hear and understand speech in all listening situations, even
in noise.
For more information about Cochlear and its products, please
visit http://www.Cochlear.com/US.
About Cochlear Implants
Cochlear implants are a proven
medical option for infants as young as 12 months old with profound
hearing loss in both ears, children aged two and older with
severe-to-profound hearing loss, and adults with
moderate-to-profound hearing loss in both ears. They are electronic
devices that bypass damaged hair cells in the inner ear, or
cochlea, and stimulate the hearing nerve directly.
About Cochlear Limited (ASX: COH)
Cochlear is the
global leader in implantable hearing solutions. The company has a
global workforce of 2,700 people and invests more than AUS$100
million a year in research and development. Products include
hearing systems for cochlear, bone conduction and acoustic
implants.
Over 400,000 people of all ages, across more than 100 countries,
now hear because of Cochlear.
www.cochlear.com
Logo - http://photos.prnewswire.com/prnh/20130531/LA23942
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cochlear-combines-the-worlds-thinnest-cochlear-implant-platform-with-the-industrys-thinnest-full-length-electrode-300107756.html
SOURCE Cochlear Limited
